FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileRoundhill Investments - GLP-1 & Weight Loss ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
OZEM
Roundhill Investments - GLP-1 & Weight Loss ETF ETF AnalysisComprehensive ETF analysis for Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisOZEM
OZEM
Roundhill Investments - GLP-1 & Weight Loss ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
OZEM
  1. Home
  2. Screener
  3. Roundhill Investments - GLP-1 & Weight Loss ETFOZEMETF

Roundhill Investments - GLP-1 & Weight Loss ETF

ETF
🇺🇸OZEM•NASDAQ•Equity
Fund size (USD)
$57.47M
Expense Ratio
0.59%
Yield (12 mo)
1.43%
Holdings
29

Your view on OZEM

Roundhill Investments - GLP-1 & Weight Loss ETF

ETFRoundhill Investments
🇺🇸OZEM•NASDAQ•Equity
Fund size (USD)
$57.47M
Expense Ratio
0.59%
Yield (12 mo)
1.43%
Holdings
29
Your view
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

Roundhill Investments - GLP-1 & Weight Loss ETF (OZEM) is an Equity fund from Roundhill Investments, listed since 2024, with $57.5M in assets under management, a 0.59% expense ratio and a NAV of $31.40 USD.

Overview for Roundhill Investments - GLP-1 & Weight Loss ETF

Fund Type
ETF
Fund Issuer
Roundhill Investments
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
May 21, 2024
Domicile
US
Website
roundhillinvestments.com/etf/ozem
Fund Type
ETF
Fund Issuer
Roundhill Investments
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
May 21, 2024
Domicile
US
Website
roundhillinvestments.com/etf/ozem
Fund Type
ETF
Fund Issuer
Roundhill Investments
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
May 21, 2024
Domicile
US
Website
roundhillinvestments.com/etf/ozem

About this fund

Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

0.59%

Yield (12 mo)

1.43%

Fund size

$57.47M

Fund Details

NAV$31.40 USD
Holdings29
Average Volume14.9K
Inception DateMay 21, 2024
Asset ClassEquity
Fund IssuerRoundhill Investments
DomicileUS
ISINUS77926X8829
CUSIP77926X882
NAV CurrencyUSD

Expense Ratio

0.59%

Dividend Yield (TTM)

1.43%

Assets Under Management

$57.47M

NAV

$31.40 USD

Holdings

29

Average Volume

14.9K

Inception Date

May 21, 2024

Asset Class

Equity

Fund Issuer

Roundhill Investments

Domicile

US

ISIN

US77926X8829

CUSIP

77926X882

NAV Currency

USD

Expense Ratio

0.59%

Dividend Yield (TTM)

1.43%

Assets Under Management

$57.47M

NAV

$31.40 USD

Holdings

29

Average Volume

14.9K

Inception Date

May 21, 2024

Asset Class

Equity

Fund Issuer

Roundhill Investments

Domicile

US

ISIN

US77926X8829

CUSIP

77926X882

NAV Currency

USD

Distributions · last 12 months

Irregular · 1 payment

Ex-datePaidAmount
Dec 30, 2025Dec 31, 2025$0.4099
Total, 12 months$0.41 a share

Dividend yield (TTM) 1.43% = $0.41 paid per share in the 12 months to Nov 21, 2026 ÷ the $28.76 price. Past distributions; future payments can differ.

Data last updated: Nov 15, 2026, 08:10 AM

Sectors

How the fund's assets are split across sectors.

1 sectors
  • 1Healthcare
    100.0%

Top sector

Healthcare

Top weight

100.0%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

24 positions
1LLYEli Lilly & Co
20.55%
2NVONovo Nordisk A/S
10.70%
34519.TChugai Pharmaceutical Co Ltd
7.38%
4128940.KSHanmi Pharm Co Ltd
7.30%
5PFEPfizer Inc
5.85%
61093.HKCSPC Pharmaceutical Group Ltd
4.88%
7KLRAKailera Therapeutics Inc
4.40%
81276.HKJiangsu Hengrui Pharmaceuticals Co Ltd
3.93%
93692.HKHansoh Pharmaceutical Group Co Ltd
3.66%
10VKTXViking Therapeutics Inc
3.63%
111672.HKAscletis Pharma Inc
3.33%
12AZNAstraZeneca PLC
3.30%
13AMGNAmgen Inc
3.03%
14ZEAL.COZealand Pharma A/S
2.92%
15ROP.SWRoche Holding AG
2.87%

Concentration

Top 10 Weight72.29%
1LLYEli Lilly & Co
20.55%
2NVONovo Nordisk A/S
10.70%
34519.TChugai Pharmaceutical Co Ltd
7.38%
4128940.KSHanmi Pharm Co Ltd
7.30%
5PFEPfizer Inc
5.85%
61093.HKCSPC Pharmaceutical Group Ltd
4.88%
7KLRAKailera Therapeutics Inc
4.40%
81276.HKJiangsu Hengrui Pharmaceuticals Co Ltd
3.93%
93692.HKHansoh Pharmaceutical Group Co Ltd
3.66%
10VKTXViking Therapeutics Inc
3.63%
111672.HKAscletis Pharma Inc
3.33%
12AZNAstraZeneca PLC
3.30%
13AMGNAmgen Inc
3.03%
14ZEAL.COZealand Pharma A/S
2.92%
15ROP.SWRoche Holding AG
2.87%

Top 10 Weight

72.29%

1LLYEli Lilly & Co
20.55%$10.89M
2NVONovo Nordisk A/S
10.70%$5.67M
34519.TChugai Pharmaceutical Co Ltd
7.38%$3.91M
4128940.KSHanmi Pharm Co Ltd
7.30%$3.87M
5PFEPfizer Inc
5.85%$3.10M
61093.HKCSPC Pharmaceutical Group Ltd
4.88%$2.59M
7KLRAKailera Therapeutics Inc
4.40%$2.33M
81276.HKJiangsu Hengrui Pharmaceuticals Co Ltd
3.93%$2.08M
93692.HKHansoh Pharmaceutical Group Co Ltd
3.66%$1.94M
10VKTXViking Therapeutics Inc
3.63%$1.92M
111672.HKAscletis Pharma Inc
3.33%$1.76M
12AZNAstraZeneca PLC
3.30%$1.75M
13AMGNAmgen Inc
3.03%$1.61M
14ZEAL.COZealand Pharma A/S
2.92%$1.55M
15ROP.SWRoche Holding AG
2.87%$1.52M

Top 10 Weight

72.29%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on20 funds
FundAsset classExpense ratioAssetsHoldings
OZEMRoundhill Investments - GLP-1 & Weight Loss ETFThis fundEquity0.59%$57M29

Comparable funds

  • CEFZRiverNorth Active Income ETFEquity2.82%$40M42
  • FLAXFranklin FTSE Asia ex Japan ETFEquity0.19%$79M1,581
  • HOMZHoya Capital Housing ETFEquity0.30%$32M102
  • KEMQKraneShares Emerging Markets Consumer Technology ETFEquity0.79%$22M62
  • NBJPNeuberger Berman Japan Equity ETFEquity1.92%$121M55
  • NIXTResearch Affiliates Deletions ETFEquity0.29%$72M0
  • NTSEWisdomTree Emerging Markets Efficient Core FundAlternatives0.34%$51M437
  • PSTRPeakshares Sector Rotation ETFEquity2.88%$67M0

More Roundhill Investments ETFs

  • XDIVRoundhill Investments - S&P 500 No Dividend Target ETFEquity0.20%$101M0
  • XDTERoundhill Investments - S&P 500 0DTE Covered Call Strategy ETFEquity0.97%$305M6
  • XPAYRoundhill Investments - S&P 500 Target 20 Managed Distribution ETFEquity0.49%$183M6
  • YBTCRoundhill Investments - Bitcoin Covered Call Strategy ETFAlternatives0.95%$129M6
  • YETHRoundhill Investments - Ether Covered Call Strategy ETFAlternatives0.96%$44M6
  • AAPWRoundhill Investments - AAPL WeeklyPay ETFEquity1.00%$42M5
  • AMDWRoundhill Investments - AMD WeeklyPay ETFEquity1.00%$140M5
  • AMZWRoundhill Investments - AMZN WeeklyPay ETFEquity1.00%$34M4
  • ARMWRoundhill ARM WeeklyPay ETFEquity1.00%$24M5
  • AVGWRoundhill Investments - AVGO WeeklyPay ETFEquity1.00%$44M5
  • BETZRoundhill Investments - Sports Betting & iGaming ETFEquity0.75%$41M42
  • BRKWRoundhill Investments - BRKB WeeklyPay ETFEquity1.00%$16M5
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.